Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barbara Holz

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
Journal of Cancer Research and Clinical Oncology|April 12, 2019
Clinical impact of PD-L1 and PD-1 expression in squamous cell cancer of the vulvaFabinshy Thangarajah, Bernd Morgenstern, Caroline Pahmeyer, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|November 22, 2018
Comparison of the genomic background of MET-altered carcinomas of the lung: biological differences and analogiesRoberta Castiglione, Christina Alidousty, Barbara Holz, et al.
Journal of Clinical Microbiology|May 29, 2015
Head-to-Head Comparison of the RNA-Based Aptima Human Papillomavirus (HPV) Assay and the DNA-Based Hybrid Capture 2 HPV Test in a Routine Screening Population of Women Aged 30 to 60 Years in GermanyThomas Iftner, Sven Becker, Klaus-Joachim Neis, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 20, 2023
KEAP1/NFE2L2 Pathway Signature Outperforms KEAP1/NFE2L2 Mutation Status and Reveals Alternative Pathway-Activating Mutations in NSCLCChristoph Arolt, Margaret Dugan, Robert Wild, et al.
NPJ Precision Oncology|November 11, 2024
Benchmark of screening markers for KEAP1/NFE2L2 mutations and joint analysis with the K1N2-scoreChristoph Arolt, Andreas H Scheel, Margaret Dugan, et al.
Histopathology|September 18, 2020
Prevalence and potential biological role of TERT amplifications in ALK translocated adenocarcinoma of the lungChristina Alidousty, Nicolai Duerbaum, Svenja Wagener-Ryczek, et al.
Journal of Clinical Microbiology|October 26, 2018
Longitudinal Clinical Performance of the RNA-Based Aptima Human Papillomavirus (AHPV) Assay in Comparison to the DNA-Based Hybrid Capture 2 HPV Test in Two Consecutive Screening Rounds with a 6-Year Interval in GermanyThomas Iftner, Klaus-Joachim Neis, Alejandra Castanon, et al.
The Journal of Pathology|June 10, 2018
Genetic instability and recurrent MYC amplification in ALK-translocated NSCLC: a central role of TP53 mutationsChristina Alidousty, Till Baar, Luciano G Martelotto, et al.
Clinical and Translational Medicine|June 15, 2024
Integrative genomic analyses of European intrahepatic cholangiocarcinoma: Novel ROS1 fusion gene and PBX1 as prognostic markerPatrick S Plum, Timo Hess, Denis Bertrand, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
Journal of Cancer Research and Clinical Oncology|April 12, 2019
Clinical impact of PD-L1 and PD-1 expression in squamous cell cancer of the vulvaFabinshy Thangarajah, Bernd Morgenstern, Caroline Pahmeyer, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|November 22, 2018
Comparison of the genomic background of MET-altered carcinomas of the lung: biological differences and analogiesRoberta Castiglione, Christina Alidousty, Barbara Holz, et al.
Journal of Clinical Microbiology|May 29, 2015
Head-to-Head Comparison of the RNA-Based Aptima Human Papillomavirus (HPV) Assay and the DNA-Based Hybrid Capture 2 HPV Test in a Routine Screening Population of Women Aged 30 to 60 Years in GermanyThomas Iftner, Sven Becker, Klaus-Joachim Neis, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 20, 2023
KEAP1/NFE2L2 Pathway Signature Outperforms KEAP1/NFE2L2 Mutation Status and Reveals Alternative Pathway-Activating Mutations in NSCLCChristoph Arolt, Margaret Dugan, Robert Wild, et al.
NPJ Precision Oncology|November 11, 2024
Benchmark of screening markers for KEAP1/NFE2L2 mutations and joint analysis with the K1N2-scoreChristoph Arolt, Andreas H Scheel, Margaret Dugan, et al.
Histopathology|September 18, 2020
Prevalence and potential biological role of TERT amplifications in ALK translocated adenocarcinoma of the lungChristina Alidousty, Nicolai Duerbaum, Svenja Wagener-Ryczek, et al.
Journal of Clinical Microbiology|October 26, 2018
Longitudinal Clinical Performance of the RNA-Based Aptima Human Papillomavirus (AHPV) Assay in Comparison to the DNA-Based Hybrid Capture 2 HPV Test in Two Consecutive Screening Rounds with a 6-Year Interval in GermanyThomas Iftner, Klaus-Joachim Neis, Alejandra Castanon, et al.
The Journal of Pathology|June 10, 2018
Genetic instability and recurrent MYC amplification in ALK-translocated NSCLC: a central role of TP53 mutationsChristina Alidousty, Till Baar, Luciano G Martelotto, et al.
Clinical and Translational Medicine|June 15, 2024
Integrative genomic analyses of European intrahepatic cholangiocarcinoma: Novel ROS1 fusion gene and PBX1 as prognostic markerPatrick S Plum, Timo Hess, Denis Bertrand, et al.
Pageof 2